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Case Report
Neuropsychiatric Presentation of COVID-19:
A Case Report of Disinhibition in an Acute
SARS-CoV-2 Infection
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Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral infection is notable for
a high degree of symptom diversity. Emerging evidence suggests viral invasion of the central
nervous system. Therefore, serious neurological and psychiatric manifestations are anticipated. We present the case of a 67-year-old male physician who has a history of stable bipolar disorder for decades and was recently hospitalized for persistent COVID-19 symptoms
with documented positive serology. He presented with new and acute onset neuropsychiatric symptoms of disinhibition proximate to the viral infection. We postulate neuroinvasion
as the putative origin of the patient’s psychiatric instability. Furthermore, an investigation
is needed to expand upon our understanding of the potential for neuropsychiatric morbidity
related to SARS-CoV-2 for prompt diagnosis and appropriate management. There are also
no current studies addressing the risks for neurological and psychiatric symptomatology in
SARS-CoV-2 infected patients with persistent chronic mental illness.
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Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents with commonly
known symptoms of fever, cough, sore throat
and, in severe cases, respiratory insufficiency
or failure.1 Emerging evidence of neurological
symptoms has demonstrated the ability to
affect other parts of the body. Reports now
indicate associated neurological symptoms,
such as anosmia, ageusia and Guillian-Barre
syndrome. Other encephalopathic findings include dizziness, headache, delirium, changes in
level of consciousness and seizures. Similar to
other viral infections, SARS-CoV-2 is involved in
the etiology of encephalitis, necrotizing hemorrhagic encephalopathies and ischemic strokes.
Therefore, evidence indicates the capability of
neuroinvasion.2 Mechanisms of damage involve
both its direct central nervous system (CNS)

invasion and its indirect effect via inflammation, hypercoagulability, receptor inhibition3 and
immune cascade.4 The impact of SARS-CoV-2
infection on cranial nerves, blood flow and
brain regulatory systems, with resultant severe
inflammation and increased risk for permanent
lesions, raises concern for significant psychiatric comorbidity.

Case Presentation

The patient is a 67-year-old male with a past
psychiatric history of bipolar disorder type I in
remission for the last 10 years. The patient had
been asymptomatic and fully compliant with
lithium monotherapy. His past medical history
includes chronic stable small lacunar infarct,
familial tremor, hyperlipidemia, benign prostatic hyperplasia (BPH), diabetes mellitus II, renal
cell carcinoma and status post partial nephrec-
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tomy. The patient presented to the hospital
with 3 days onset of midsternal pressure, persistent dry cough, shortness of breath and lower back pain. He was found with bilateral lower
lung atelectasis and positive COVID infection
(confirmed with COVID IgG and IgM antibody
testing). The patient also complained of mood
changes that co-occurred with the respiratory
symptoms. He noted unusual hyper-verbosity,
amicability, sarcasm, mildly decreased impulse
control and “emotional disinhibition.” Sleep,
appetite and energy remained intact. Due to
his concerns about potential stress, he decided
to increase his home dose of lithium carbonate from 450 mg daily to 900 mg daily. The
patient has always maintained a stable lithium
level around 0.5 mEq/L during the previous
years. During the admission, the patient denied
any other neurological, medical or psychiatric
symptoms. He also denied fever, chills, nausea,
vomiting, diarrhea, abdominal pain and urinary
symptoms. There were no indicators of lithium
toxicity or other manifestations of his chronic
medical conditions during this hospitalization.
Physical exam and laboratory findings are presented in Table 1.

Treatment Plan

The patient received supportive treatment
during the hospitalization; antibiotics, hydroxychloroquine and steroids were withheld due to
all inflammatory markers on labs being within
normal limits and chest X-ray indicating only
chronic changes. Consultation Psychiatry was
consulted due to his distress and disinhibition.
Pseudobulbar affect and other psychiatric disorders were ruled out. Brain imaging revealed
no acute changes. The patient was discharged
with a prescription for lithium 450 mg twice
daily, aripiprazole 5 mg daily (initiated to help
address disinhibition) and benzonatate for a
persistent cough.

Post-Discharge Status and Follow Up

At the 2-week post-hospitalization psychiatric
follow-up, the patient reported better mood
control. However, he continued to present mini
episodes of emotional hypersensitivity with
tearfulness, in particular when watching movies and the news or when listening to music.
He was not grandiose or hyperverbal. Other
elements of the MSE mental status examination were unremarkable. His physical condition
was notable for a persistent but improving dry
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cough. He was afebrile and in no respiratory
distress with a pulse oximetry reading of 98%
on room air. The lithium carbonate was reduced
to 625 mg per day, and aripiprazole was continued at 5 mg per day.
At the 7-week post-hospitalization psychiatric
follow-up, the patient achieved complete remission of neuropsychiatric symptoms. The aripiprazole was discontinued, and the dosage of
lithium was reduced to his historical dosage of
450 mg per day. The patient was able to recover gradually and successfully from the medical
and psychiatric conditions after hospitalization.

Discussion

The association of various viral infections to
neuropsychiatric illness is well established.
Data supports the association between respiratory viruses, particularly influenza, and
neuropsychiatric conditions, including acute
encephalopathy (seizures and coma, with or
without multiorgan failure) and transient neuropsychiatric disorders (delirium and abnormal
behaviors)5 such as schizophrenia.6,7 Prenatal
influenza exposure shows a subsequent heightened risk for the development of schizophrenia,
bipolar disorder, autism and mood disorders.8
SARS-CoV, the strain responsible for the
initial SARS outbreak in 2003, had reported
psychiatric morbidities, including persistent
depression, anxiety, panic attacks, psychomotor excitement, psychotic symptoms, delirium
and suicidality.9 Additionally, previous studies
have also demonstrated that exposure to the
coronavirus may be a comorbid risk factor in
neuropsychiatric disease due to the presence of
immunoglobulin G (IgG) response in patients
with recent onset of psychotic symptoms.10
SARS-CoV-2 is one of many strains of coronavirus, all of which share the same large, enveloped, nonpigmented positive-sense ribonucleic
acid structure and pathway, clinically manifesting most typically in the gastrointestinal
and respiratory tracts.11 More recent evidence
indicates neurological manifestations, including, but not limited to, headache, disturbed
consciousness and paresthesia, in about a third
of the affected population.12 Initially, fatalities
were attributed to multiorgan failure with
homeostatic dysregulation. Studies now show
that CNS involvement, with subsequent brainstem damage-induced respiratory distress, is
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Table 1. Physical examination with laboratory findings of the patient with pertinent laboratory
values on admission and upon discharge.
Physical Exam
General Assessment

Awake, alert and oriented. No acute distress.

Vital Signs

Heart rate: 67 beats per minute
Blood pressure: 135/88 mmHg
Temperature: 98.1° F
Respiratory rate: 16 breaths per minute
O2 saturation: 98% (ranged from 93%–99%)
Body mass index: 28.4 kg/m2

Labs

Admission
Platelet count: 141 u/L

Discharge
Platelet count: 155 u/L

D-dimer: <200 ng/mLDDU
Procalcitonin: <0.05 ng/mL
Lipase: 122 U/L
C-reactive protein: <0.05 mg/dL
Ferritin: 117 ng/mL
Troponin: <0.012 ng/mL
CMP: unremarkable
BUN: 18 mg/dl

BUN: 17 mg/dl

CR: 0.9 mg/dl

CR: 0.9 mg/dl

AST: 21 Units/L

AST: 25 Units/L

ALT: 21 Units/L

ALT: 25 Units/L

Lithium level: 0.9 mmol/L
COVID-19 PCR: Positive
ECG

Prolonged QTc: 472 ms

Imaging

Chest X-ray: Bibasilar infiltrates, likely secondary to atelectasis

Physical Exam

Unremarkable

Mental Status Exam

Patient is alter, fully oriented, with no confusion, delirium, obsessions, compulsions, hallucinations nor internal stimuli noted.

potentially one of the major contributors to
mortality with CNS involvement leading to
advanced mortality rates.11,13
Previous strains of the coronavirus have shown
neurotropic potential.14 The neurotropic nature of the virus is suspected to be most likely
via circulatory system exploitation and host
cell entrance through the utilization of cellular receptor angiotensin-converting enzyme 2
(ACE2). ACE2 is widespread within the human body, including airway epithelia, vascular
endothelia, lung parenchyma, small intestine
cells and kidney cells with expression noted
in glial cells and neurons. Although common

pathophysiology to all strains of the coronavirus, SARS-CoV-2 holds a 10- to 20-fold higher
binding affinity to the ACE2. These factors
likely contribute to the neuronal damage,
cerebral capillary endothelial rupture and brain
bleeding seen in many patients affected by
COVID-19.11,13,15,16 The similar neurotropic pathophysiology between the two strains with an
exacerbated response along with previously
reported psychiatric sequelae of SARS-CoV,
deem neuroinvasion a plausible postulation of
the patient’s psychiatric instability in this case
presentation. Our final diagnosis is disinhibition
in the context of acute SARS-CoV-2 infection.
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Conclusion

We describe neuropsychiatric instability proximate to SARS-CoV-2 infection in a patient with
bipolar disorder who had been stable for decades. As he recovered from the infection and
his physical symptoms resolved, so too did his
psychiatric findings. The authors postulate neuroinvasion and neuroinflammation as the putative origin of the patient’s acute psychiatric
mood instability. Current clinical guidelines and
effective treatment for patients with COVID19-induced psychiatric disorders do not exist.
Continued investigation is needed to expand
upon our understanding of the potential for
psychiatric morbidity related to SARS-CoV-2
infection for prompt and appropriate diagnosis
and management. Furthermore, respiratory
symptomatology has been the focus of diagnosis and management in patients infected
with SARS-CoV-2. Appropriate comprehensive
screening and clinical examination that includes
the psychiatric and neurological systems in
patients infected with SARS-CoV-2 is imperative and perhaps mandatory in patients with
previous neuropsychiatric complaints.
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